健艾仕

GNS Biotech, officially known as Jian Ai Shi (Beijing) Biotechnology, is a clinical-stage biotechnology company focused on the development of innovative immune cell therapies for cancer. The company utilizes its proprietary cell engineering platforms to develop chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) therapies. Its lead program, GNS-001, targets CD19 for the treatment of B-cell malignancies and has progressed into Phase 1/2 clinical trials. GNS Biotech is also advancing GNS-002, a BCMA-targeted CAR-T for multiple myeloma, and several TCR-T programs for solid tumors. Headquartered in Beijing, the company has secured backing from prominent venture capital firms to support its mission of providing effective and accessible cell-based treatments.